ALEXIS Biochemicals: W84 dibromide

ALX-550-399

Revised 16-Jan-06

W84 dibromide
SYNONYMS	N,N’-Bis[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-N,N,N’,N’-tetramethyl-1,6-hexanediamminium dibromide Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium] dibromide
PRODUCT LINE	Neurobiology
PRODUCT CATEGORY	Acetylcholine Receptors (Muscarinic) / Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-550-399-M005		5 mg	65.00 USD

Product Specification

FORMULA:	C₃₂H₄₄Br₂N₄O₄
MW:	708.5
CAS NUMBER:	21093-51-6
PURITY:	≥98% (HPLC)
APPEARANCE:	White to off-white solid.
SOLUBILITY:	Soluble in DMSO, water or aqueous buffer.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+4°C
HANDLING:	After reconstitution, prepare aliquots and store at -20°C.

Product Description

One of the first potent allosteric modulator of muscarinic receptors, selective for M2-receptors. Retards the dissociation of the antagonist N-methylscopolamine. Affinity for the free receptor is about 10-fold lower than with dimethyl-W84 (Prod. No. ALX-550-400) and about 100-fold lower than with naphmethonium (Prod. No. ALX-550-401). pK_A=6.19, P(αK_A)=5.73, pEC_50,diss=5.87.

Product Specific Literature References

Search for lead structures to develop new allosteric modulators of muscarinic receptors: C. Trankle, et al.; J. Pharmacol. Exp. Ther. 279, 926 (1996) Abstract
M2 receptor binding of the selective antagonist AF-DX 384: possible involvement of the common allosteric site: C. Trankle, et al.; Mol. Pharmacol. 53, 304 (1998) Abstract; Full Text
Structure-activity relationships in a series of bisquaternary bisphthalimidine derivatives modulating the muscarinic M(2)-receptor allosterically: H.M. Botero Cid, et al.; J. Med. Chem. 43, 2155 (2000) Abstract
Hexamethonium-type allosteric modulators of the muscarinic receptors bearing lateral dibenzazepine moieties: R. Li, et al.; Arch. Pharm. 334, 121 (2001) Abstract
Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding: M. Muth, et al.; J. Med. Chem. 46, 1031 (2003) Abstract
Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors: C. Trankle, et al.; Mol. Pharmacol. 64, 180 (2003) Abstract; Full Text
Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupie: U. Voigtlander, et al.; Mol. Pharmacol. 64, 21 (2003) Abstract; Full Text
Contribution of lateral substituents in symmetrical and non-symmetrical heptane-bisammonio compounds to the allosteric stabilization of N-methylscopolamine binding to muscarinic M2 receptors: M. Staudt, et al.; Arch. Pharm. (Weinheim) 336, 385 (2003) Abstract
Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents: M. Muth, et al.; J. Med. Chem. 48, 2212 (2005) Abstract
Allosteric site in M(2) acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist: M. Grossmuller, et al.; Naunyn Schmiedebergs Arch. Pharmacol. In print (2005) Abstract
Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors: C. Trankle, et al.; Mol. Pharmacol. 68, 1597 (2005) Abstract
Design, Synthesis, and Action of Oxotremorine-Related Hybrid-Type Allosteric Modulators of Muscarinic Acetylcholine Receptors: T. Disingrini, et al.; J. Med. Chem. 49, 366 (2006) Abstract

General Literature References

G protein-coupled receptor allosterism and complexing: A. Christopoulos and T. Kenakin; Pharmacol. Rev. 54, 323 (2002) Abstract

Further Categories Containing This Product:

Parkinson's Disease Other Products

header picture © micronaut.ch, another CS2 website

Online Product Ordering

Clipboard [0]

Your items will be kept only for the duration of your visit.